May 07 2022 42 mins
In today's episode, I'm talking with Dr. Howard Berman, the Chief Executive Officer of Coya Therapeutics, which focuses on therapies and treatments of conditions linked to T-regulatory cells ("T-reg cells"). Right now, his team is in Phase 2B of a clinical trial for a treatment that would dramatically help patients suffering from ALS (Lou Gehrig's Disease). Howard and I discuss what on earth T-reg cells are, what he hopes to accomplish in his job at Coya, what's next for the company, and much more!
Be sure to subscribe to R is for Rare on Apple Podcasts, Spotify, or wherever you listen to podcasts! And, if you LOVE the show, be sure to leave a review!!
Follow me on Instagram - @risforrarepodcast
---
More about Dr. Howard - With over 18 years of entrepreneurial and industry experience, Dr. Berman has leveraged his past working at the interplay of science and business to bring multiple oncology drugs and therapies to market. His past achievements with AbbVie, Novartis, Eli Lilly, and MorphoSys have prepared him to lead Coya Therapeutics.
Coya Therapeutics online -- https://www.coyatherapeutics.com
--- Send in a voice message: https://podcasters.spotify.com/pod/show/annie-watson/message